

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 22, 2025

Hep 3B2.1-7

RRID:CVCL_0326

Type: Cell Line

Proper Citation

(RRID:CVCL_0326)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0326

Proper Citation: (RRID:CVCL_0326)

Sex: Male

Defining Citation: [PMID:233137](#), [PMID:2439335](#), [PMID:3023526](#), [PMID:3431441](#), [PMID:6248960](#), [PMID:6275024](#), [PMID:6288577](#), [PMID:7972006](#), [PMID:8050184](#), [PMID:8224613](#), [PMID:8389256](#), [PMID:8835345](#), [PMID:9290701](#), [PMID:9359923](#), [PMID:10523694](#), [PMID:11050057](#), [PMID:12029633](#), [PMID:15767549](#), [PMID:20215515](#), [PMID:20454443](#), [PMID:20937217](#), [PMID:22460905](#), [PMID:23505090](#), [PMID:23887712](#), [PMID:24116068](#), [PMID:25574106](#), [PMID:25877200](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29610054](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31063779](#), [PMID:31068700](#), [PMID:31378681](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:32899426](#), [PMID:34320349](#), [PMID:35839778](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: miRNA expression profiling., Omics: Genome sequenced., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Karyotypic information: Has lost chromosome Y., Population: African American., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Liver Cancer Model Repository (LIMORE)., Part of: JFCR45 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Name: Hep 3B2.1-7

Synonyms: Hep 3B2_1-7, Hep 3B 2.1-7, HEP3B217, Hep 3B2, HEP-3B2, HEP3B2, Hep-3B, HEP-3B, Hep 3B, Hep3B, HEP3B

Cross References: BTO:BTO_0000972, CLO:CLO_0003702, CLO:CLO_0003703, CLO:CLO_0003710, EFO:EFO_0002205, EFO:EFO_0022386, MCCL:MCC:0000221, CLDB:cl1627, CLDB:cl1628, CLDB:cl1629, CLDB:cl1630, AddexBio:C0015001/45, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HB-8064, BCRC:60434, BCRJ:0357, BioGRID_ORCS_Cell_line:810, BioSample:SAMN03473193, BioSample:SAMN10988098, cancercellines:CVCL_0326, CCRID:1101HUM-PUMC000376, CCRID:1101HUM-PUMC000474, CCRID:1102HUM-NIFDC00059, CCRID:3101HUMSCSP5045, CCRID:3101HUMTCHu106, CCRID:4201HUM-CCTCC00070, CCTCC:GDC0070, Cell_Model_Passport:SIDM00672, CGH-DB:454-3, CGH-DB:9069-4, ChEMBL-Cells:ChEMBL4106361, ChEMBL-Targets:ChEMBL4296437, CLS:305141, Cosmic:873401, Cosmic:928140, Cosmic:934549, Cosmic:948066, Cosmic:979729, Cosmic:999851, Cosmic:1019316, Cosmic:1177682, Cosmic:1351510, Cosmic:1518225, Cosmic:1628385, Cosmic:2023864, Cosmic:2162536, Cosmic:2301557, Cosmic:2321030, Cosmic:2668282, Cosmic:2816904, Cosmic:2773181, Cosmic-CLP:1240147, DepMap:ACH-000625, DSMZ:ACC-93, DSMZCellDive:ACC-93, ECACC:86062703, EGA:EGAS00001000978, GDSC:1240147, GEO:GSM207050, GEO:GSM501778, GEO:GSM565879, GEO:GSM887078, GEO:GSM888148, GEO:GSM936759, GEO:GSM1374531, GEO:GSM1669879, GEO:GSM2551564, IARC_TP53:30036, IGRhCellID:Hep3B, IZSLER:BS TCL 78, KCB:KCB 200771YJ, KCB:KCB 200942YJ, KCLB:88064, LiGeA:CCL_655, LIMORE:Hep3B, LINCS_LDP:LCL-1924, Lonza:473, PharmacDB:Hep3B2_17_538_2019, PRIDE:PXD000533, PRIDE:PXD000535, PRIDE:PXD005291, PRIDE:PXD008190, PRIDE:PXD030304, Progenetix:CVCL_0326, PubChem_Cell_line:CVCL_0326, RCB:RCB2090, TKG:TKG 0291, TOKU-E:1439, TOKU-E:3574, Ubigen:YC-D002, Wikidata:Q54882746

ID: CVCL_0326

Record Creation Time: 20250131T200405+0000

Record Last Update: 20250131T201624+0000

Ratings and Alerts

No rating or validation information has been found for Hep 3B2.1-7.

Warning: Discontinued: RCB; RCB2090

Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: miRNA expression profiling., Omics: Genome sequenced., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Karyotypic information: Has lost chromosome Y., Population: African American., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Liver

Cancer Model Repository (LIMORE)., Part of: JFCR45 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3930 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Zhu X, et al. (2024) NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers. *Cell chemical biology*, 31(6), 1203.

Yang Q, et al. (2024) Reduced representative methylome profiling of cell-free DNA for breast cancer detection. *Clinical epigenetics*, 16(1), 33.

Song M, et al. (2024) DNA of Neutrophil Extracellular Traps Binds TMCO6 to Impair CD8+ T-cell Immunity in Hepatocellular Carcinoma. *Cancer research*, 84(10), 1613.

Jiang Z, et al. (2024) CREB3L4 promotes hepatocellular carcinoma progression and decreases sorafenib chemosensitivity by promoting RHEB-mTORC1 signaling pathway. *iScience*, 27(2), 108843.

Qiu J, et al. (2024) Hypoxia-responsive lncRNA MIR155HG promotes PD-L1 expression in hepatocellular carcinoma cells by enhancing HIF-1 α mRNA stability. *International immunopharmacology*, 136, 112415.

Jochems F, et al. (2024) Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state. *Cell death and differentiation*.

Gleason CE, et al. (2024) Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(4), 703.

Wang J, et al. (2024) Targeting HSP70 chaperones by rhein sensitizes liver cancer to artemisinin derivatives. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 122, 155156.

Zhou Y, et al. (2024) GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. *Theranostics*, 14(9), 3470.

Zhang C, et al. (2024) Re-evaluation of the relationship between PrPc expression and patient prognosis in primary esophageal squamous cell carcinoma and primary hepatocellular carcinoma. *Scientific reports*, 14(1), 31122.

Singh AK, et al. (2024) Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(7), 1293.

Chen Z, et al. (2024) SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion. *Oncoimmunology*, 13(1), 2376264.

Lu H, et al. (2024) Carbonic anhydrase 2 facilitates sorafenib resistance by counteracting MCT4-mediated intracellular pH dysregulation in HCC. *Cell reports*, 43(12), 114996.

Frumento N, et al. (2024) Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection. *Immunity*, 57(1), 40.

Yang Y, et al. (2024) The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor. *EMBO molecular medicine*, 16(4), 885.

Hu X, et al. (2024) A gut-derived hormone regulates cholesterol metabolism. *Cell*, 187(7), 1685.

Ogega CO, et al. (2024) Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance. *Immunity*.

Chen T, et al. (2024) Protocol to analyze the role of various metabolites in impacting global RNA 5-methylcytosine levels in cultured cells by dot blot. *STAR protocols*, 5(1), 102815.

Zhou HM, et al. (2024) Inhibition of RhoGEF/RhoA alleviates regorafenib resistance and cancer stemness via Hippo signaling pathway in hepatocellular carcinoma. *Experimental cell research*, 436(1), 113956.

Chen S, et al. (2024) YTHDF3-mediated m6A modification of NKD1 regulates hepatocellular carcinoma invasion and metastasis by activating the WNT/ β -catenin signaling axis. *Experimental cell research*, 442(1), 114192.